Market News Today — AI-Curated Stock & Crypto Headlines

Moderna's stock rises after the FDA announces it will review the company's seasonal flu vaccine candidate, a reversal from its earlier rejection.

The FDA has agreed to review Moderna's mRNA flu vaccine application, paving the way for its potential approval and availability for the upcoming influenza season.

Moderna's stock surged after the FDA agreed to review its flu-vaccine candidate, reversing a previous decision, following concessions made by the company.

The FDA is considering shifting prescription medications to over-the-counter (OTC) status, starting with non-addictive and non-hazardous drugs, aiming for changes this year.

Eli Lilly is stockpiling its GLP-1 weight loss pills ahead of FDA approval, potentially indicating a positive outcome for the drug's regulatory review.

Moderna's seasonal vaccine development is facing challenges due to the FDA's current review process, which has been deemed 'risky' by an analyst.

Moderna's stock has declined due to the FDA's rejection of its application for a new seasonal flu vaccine, leaving investors puzzled about the reason behind the decision.

Moderna's experimental flu shot, mRNA-1010, has been rejected by the FDA for review, contradicting previous feedback from the regulatory agency.

Hims & Hers Health stock dropped 16% after facing a lawsuit from Novo Nordisk and FDA scrutiny, impacting investor sentiment.

The FDA has found Novo Nordisk's TV ad for its obesity pill to contain 'false or misleading' claims, prompting the agency to request immediate action from the company.

Hims & Hers has abandoned its weight-loss drug due to a potential patent infringement issue with Novo Nordisk's Wegovy, following an FDA probe.

The US FDA has announced a crackdown on copycat weight-loss drugs, specifically targeting Hims & Hers, a telehealth company that has undercut Novo Nordisk's obesity shot prices, raising concerns about regulatory compliance and market competition.